Safety and efficacy of fixed‐dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open‐label trial

BACKGROUND: Fixed‐dose combination of calcipotriol (50 μg/g; Cal) and betamethasone dipropionate (0.5 mg/g; BD) foam is approved for plaque psoriasis treatment in adults, with a paucity of data supporting use in adolescents. OBJECTIVES: To evaluate safety of 4 weeks’ treatment with Cal/BD foam in ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyger, M., Abramovits, W., Liljedahl, M., Hoejen, M.N., Teng, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496170/
https://www.ncbi.nlm.nih.gov/pubmed/32074665
http://dx.doi.org/10.1111/jdv.16233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496170/
https://www.ncbi.nlm.nih.gov/pubmed/32074665
http://dx.doi.org/10.1111/jdv.16233

Ejemplares similares